2024 ASCO® Annual Meeting Insights Hub
Meeting coverage & Vumedi’s exclusive highlights, all in one place.
ASCO® 2024 Insights: "PALOMA-2 Study - Subcutaneous Amivantamab & Lazertinib as 1L Treatment in Patients With EGFRm Advanced NSCLC"
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Sun Min Lim
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Sun Min Lim
Login to view comments.
Click here to Login